Overview

Dose Response and Receptor Selectivity of Beta-blocker Effects on Bone Metabolism

Status:
Completed
Trial end date:
2018-04-01
Target enrollment:
Participant gender:
Summary
This study is designed to answer the question as to whether the sympathetic nervous system is an important determinant of bone metabolism in humans.
Phase:
Early Phase 1
Details
Lead Sponsor:
Mayo Clinic
Treatments:
Adrenergic beta-Antagonists
Atenolol
Nebivolol
Propranolol